---
schema_version: "secwatch.filing_event.v1"
accession: "0001459839-24-000075"
form_type: "8-K"
ticker: "SIBN"
cik: "0001459839"
company_name: "SI-BONE, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:44:01.560170+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SI-BONE reports Q3 revenue $40.3M (+19% YoY); expects positive Adjusted EBITDA in Q4

## Summary
- Worldwide revenue $40.3M (+19% YoY); U.S. revenue $38.3M (+18% YoY).
- Net loss improved 34% to $6.6M; Adjusted EBITDA loss narrowed 94% to $0.2M.
- Over 1,200 active U.S. physicians (+15%); commercialized iFuse TORQ TNT for pelvic fractures.
- Updated FY2024 revenue guidance to $165-166M (prev $165-167M); expects Adj EBITDA positive in Q4.
- Refinanced $36M term loan, lowered borrowing cost, extended maturity to 2029.

## SEC filing metadata
- accession: 0001459839-24-000075
- form_type: 8-K
- ticker: SIBN
- cik: 0001459839
- company_name: SI-BONE, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1459839/000145983924000075/0001459839-24-000075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1459839/000145983924000075/sibn-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001459839-24-000075
- JSON: https://secwatch.observer/filing/0001459839-24-000075.json
- Plain text: https://secwatch.observer/filing/0001459839-24-000075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.